Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib in Neoadjuvant Therapy for ALK-Positive Lung Adenocarcinoma
NCT06785584Phase 4Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ensartinib in lung adenocarcinoma, sponsored by Fujian Medical University Union Hospital. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ensartinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT06785584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06785584.